WallStSmart

Edwards Lifesciences Corp (EW)vsNokia Corp ADR (NOK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nokia Corp ADR generates 217% more annual revenue ($20.00B vs $6.30B). EW leads profitability with a 17.4% profit margin vs 4.0%. NOK appears more attractively valued with a PEG of 1.15. EW earns a higher WallStSmart Score of 61/100 (C+).

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 7.5Value: 6.0Quality: 4.8
Piotroski: 2/9

NOK

Hold

40

out of 100

Grade: F

Growth: 2.7Profit: 4.5Value: 5.3Quality: 7.0
Piotroski: 4/9Altman Z: 1.65
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+69.7%)

Margin of Safety

+69.7%

Fair Value

$261.90

Current Price

$79.96

$181.94 discount

UndervaluedFair: $261.90Overvalued
NOKUndervalued (+16.7%)

Margin of Safety

+16.7%

Fair Value

$8.81

Current Price

$12.35

$3.54 discount

UndervaluedFair: $8.81Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW2 strengths · Avg: 9.0/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

NOK3 strengths · Avg: 8.7/10
Market CapQuality
$74.25B9/10

Large-cap with strong market position

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
44.7x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

NOK4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
2.4%4/10

2.4% revenue growth

Altman Z-ScoreHealth
1.654/10

Distress zone — elevated risk

Return on EquityProfitability
3.7%3/10

ROE of 3.7% — below average capital efficiency

Profit MarginProfitability
4.0%3/10

4.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bull Case : NOK

The strongest argument for NOK centers on Market Cap, Debt/Equity, Price/Book. PEG of 1.15 suggests the stock is reasonably priced for its growth.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 44.7x leaves little room for execution misses.

Bear Case : NOK

The primary concerns for NOK are Revenue Growth, Altman Z-Score, Return on Equity. A P/E of 83.1x leaves little room for execution misses. Thin 4.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

EW profiles as a growth stock while NOK is a value play — different risk/reward profiles.

EW carries more volatility with a beta of 0.87 — expect wider price swings.

EW is growing revenue faster at 16.7% — sustainability is the question.

NOK generates stronger free cash flow (629M), providing more financial flexibility.

Bottom Line

EW scores higher overall (61/100 vs 40/100), backed by strong 17.4% margins and 16.7% revenue growth. NOK offers better value entry with a 16.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Nokia Corp ADR

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Nokia Corporation offers fixed and mobile network solutions globally. The company is headquartered in Espoo, Finland.

Visit Website →

Want to dig deeper into these stocks?